Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
28 Novembro 2023 - 10:00AM
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage
biopharmaceutical company developing novel fatty acid synthase
(FASN) inhibitors that target dysfunctional metabolic pathways,
will present preclinical data at the 7th Obesity and NASH Drug
Development Summit on November 28, 2023, in Boston. The
presentation details an evaluation of Sagimet’s FASN inhibitor
alone or in combination with semaglutide in a preclinical mouse
model of nonalcoholic steatohepatitis (NASH), using an artificial
intelligence (AI) based digital pathology platform (FibroNestTM,
Pharmanest Inc., Princeton, USA) to assess fibrosis.
“We are pleased to report strong preclinical combination results
demonstrating that the FASN inhibitor alone, not semaglutide, was
responsible for significant reduction of liver fibrosis, a
predictor of outcome in NASH,” said Eduardo Bruno Martins, M.D.,
D.Phil., Sagimet’s Chief Medical Officer. “Building upon the
preclinical data presented at AASLD - The Liver Meeting earlier
this month, our oral presentation includes transcriptomic profiling
analysis which suggests that the FASN inhibitor and semaglutide
combination not only has an additive effect but also provides
distinct MOAs that could potentially benefit patients living with
NASH and dysmetabolic syndrome. We believe that these preclinical
data support further clinical evaluation. Our immediate focus
remains on advancing denifanstat as a potential monotherapy and we
remain on track to report topline results of our FASCINATE-2 Phase
2b clinical trial, including biopsy data, in the first quarter of
next year.”
Details of the oral presentation include:
Title: Evaluation of FASN inhibitor &
GLP-1 Combination in Preclinical Mouse
ModelPresenter: Wen-Wei Tsai,
Ph.D.Presentation Date: The oral presentation is
scheduled for 12:30 p.m. ET on Tuesday, November 28,
2023
The presentation will be available in the “Posters and
Publications” section of Sagimet’s website.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing
novel fatty acid synthase (FASN) inhibitors that target
dysfunctional metabolic pathways in diseases resulting from the
overproduction of the fatty acid, palmitate. Sagimet’s lead drug
candidate, denifanstat, is an oral, once-daily pill and selective
FASN inhibitor in development for the treatment of NASH, for which
there are no treatments currently approved in the United States or
Europe. Denifanstat is currently being tested in FASCINATE-2, a
Phase 2b clinical trial in NASH with liver biopsy as the primary
endpoint. For additional information about Sagimet, please visit
www.sagimet.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of, and made pursuant to the safe harbor provisions of,
The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements
of historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding: the expected timing of the presentation of data from
ongoing clinical trials, Sagimet’s clinical development plans and
related anticipated development milestones, Sagimet’s cash and
financial resources and expected cash runway. These statements
involve known and unknown risks, uncertainties and other important
factors that may cause Sagimet’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. In some cases, these statements can be
identified by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions.
The forward-looking statements in this press release are only
predictions. Sagimet has based these forward-looking statements
largely on its current expectations and projections about future
events and financial trends that Sagimet believes may affect its
business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Sagimet’s control, including, among
others: the clinical development and therapeutic potential of
denifanstat or any other drug candidates Sagimet may develop;
Sagimet’s ability to advance drug candidates into and successfully
complete clinical trials, including its FASCINATE-2 Phase 2b
clinical trial; Sagimet’s relationship with Ascletis, and the
success of its development efforts for denifanstat; the accuracy of
Sagimet’s estimates regarding its capital requirements; and
Sagimet’s ability to maintain and successfully enforce adequate
intellectual property protection. These and other risks and
uncertainties are described more fully in the “Risk Factors”
section of Sagimet’s most recent filings with the Securities
and Exchange Commission and available at www.sec.gov. You
should not rely on these forward-looking statements as predictions
of future events. The events and circumstances reflected in these
forward-looking statements may not be achieved or occur, and actual
results could differ materially from those projected in the
forward-looking statements. Moreover, Sagimet operates in a dynamic
industry and economy. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict
all risk factors and uncertainties that Sagimet may face. Except as
required by applicable law, Sagimet does not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Contact:
Maria YonkoskiICR
Westwicke203-682-7167maria.yonkoski@westwicke.com
Sagiment Biosciences (NASDAQ:SGMT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sagiment Biosciences (NASDAQ:SGMT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024